CellCept 500 mg powder for concentrate for solution for infusion
Sponsors
Eledon Pharmaceuticals Inc., Biocompatibles UK Limited
Conditions
Hepatocellular CarcinomaProphylaxis of Renal Allograft Rejection
Phase 2
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Active, not recruitingCTIS2023-503336-41-00
Start: 2023-11-29Target: 101Updated: 2025-07-22
An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
Active, not recruitingCTIS2023-508945-41-00
Start: 2023-10-11Target: 81Updated: 2026-01-27